Full Press Release Details
New No Fingerstick 1 Sensor Integrates with Both the MiniMed 780G System and the Smart InPen System
"We look forward to having multiple ways to help our patients manage their diabetes as we know that patient needs and preferences can vary greatly," said Prof. Goran Petrovski , M.D., MSc, Ph.D., diabetologist – Endocrinology Unit, Sidra Medicine , Doha, Qatar . "Living with diabetes is challenging, and these innovations are finding new ways to reduce the work that people must do every day to stay healthy."
For individuals who prefer automated insulin delivery via an insulin pump, the MiniMed 780G system with Guardian 4 sensor will automatically adjust and correct insulin delivery every 5 minutes with no fingersticks 5 . By pairing the MiniMed 780G system with the recently launched Medtronic Extended infusion set that is indicated for up to 7 days, twice as long as current infusion sets, insulin pump users may need to perform 70 fewer set changes per year 6 . With these two innovations, Medtronic offers the only pump that adjusts and corrects every 5 minutes with an infusion set that lasts twice as long –improving the experience of using insulin pump therapy.
In the United States , Guardian 4 sensor and the MiniMed 780G system are investigational use only and not approved for sale.
About the Diabetes Business at Medtronic ( www.medtronicdiabetes.com ) Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in approximately 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
| Contacts: | |
| Pamela Reese | Ryan Weispfenning |
| Public Relations | Investor Relations |
| +1-818-576-3398 | +1-763-505-4626 |
SOURCE Medtronic plc